New hope for blood cancer patients who've run out of options
NCT ID NCT04798339
Summary
This study is testing whether combining two drugs—canakinumab and darbepoetin alfa—can help patients with lower-risk myelodysplastic syndromes (MDS) who didn't respond to standard anemia treatments. The research aims to find a safe dose and see if this combination can reduce the need for blood transfusions and improve blood counts. It's for patients who have already tried and failed erythropoietin stimulating agents.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.